Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.81
+$0.0153 · +1.93%
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Previous close
$0.81
+$0.0153 · +1.93%
Regular session · ET · Market data may be delayed.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Day range
Current $0.81
52-week range
Current $0.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
51
Mixed
Risk
69
High Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Day range
Current $0.81
52-week range
Current $0.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (SGD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 319.2K SGD | 69.5K SGD | 509.13K SGD | 365.6K SGD | — |
| Cost of goods sold | 1.21M SGD | 17.12K SGD | 3.74K SGD | 109.04K SGD | 3.5K SGD |
| Gross profit | −886.56K SGD | 52.38K SGD | 505.39K SGD | −109.04K SGD | 110.29K SGD |
| Research and development | 2.18M SGD | 1.91M SGD | 1.59M SGD | 1.52M SGD | 1.09M SGD |
| Selling, general, and administrative | 1.44M SGD | 1.27M SGD | 490.49K SGD | 596.51K SGD | 588.46K SGD |
| Operating expenses | 3.63M SGD | 3.18M SGD | 2.08M SGD | 2.17M SGD | 1.27M SGD |
| Interest income | 121.92K SGD | 317.67K SGD | 281.49K SGD | 2.05K SGD | 3.39K SGD |
| Interest expense | 20.57K SGD | 20.31K SGD | 50.52K SGD | 122.15K SGD | 118.39K SGD |
| Depreciation and amortization | 223.17K SGD | 125.05K SGD | 102.51K SGD | 394.7K SGD | 329.74K SGD |
| Operating income | −4.52M SGD | −3.13M SGD | −1.58M SGD | −2.28M SGD | −1.16M SGD |
| Net income | −3.92M SGD | −2.52M SGD | −4.14M SGD | −3.06M SGD | −2.07M SGD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
